【私募调研记录】世诚投资调研九洲药业、澜起科技

Group 1: Jiuzhou Pharmaceutical - Jiuzhou Pharmaceutical indicated that the suspension of the PLI plan in India benefits raw material manufacturers in other countries, with domestic raw material prices gradually stabilizing [1] - The number of new CDMO projects in 2024 is expected to grow by 15% year-on-year, with contract amounts increasing by 20% [1] - CDMO business revenue is close to 3.9 billion yuan, with nearly 80% coming from overseas, primarily from European clients [1] - The company anticipates a recovery in CDMO gross margin to around 40% by 2025 [1] - In Q1, the overall capacity utilization rate was approximately 60%, with capital expenditures for 2025 controlled at 500-600 million yuan [1] - The second phase of the commercial production capacity for the peptide department is expected to be operational by September 2025 [1] Group 2: Lanke Technology - Lanke Technology plans to focus on the development of computing power chips for intelligent hardware over the next 5-10 years, emphasizing the importance of interconnect chips [2] - The demand for DDR5 memory interface chips is expected to significantly increase due to trends in the AI industry [2] - The company has invested in the development of PCIe Switch chips and anticipates continued growth in demand for PCIe Retimer chips, primarily driven by AI server shipments [2] - Lanke Technology's core business maintains high quality, with major products being high value-added, resulting in a high gross margin [2] - The company has linked the market value to executive performance evaluations for three consecutive years to align management interests with shareholder interests [2]